Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotoxins against solid tumors.

R Pirker1

  • 1Second Medical Clinic, University of Vienna, Austria.

Journal of Cancer Research and Clinical Oncology
|January 1, 1988
PubMed
Summary

Immunotoxins, antibody-toxin conjugates, show promise as anticancer agents by targeting tumor cells. Challenges in delivery and potential side effects need to be addressed for effective clinical use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New onset of systemic lupus erythematosus following COVID-19 mRNA vaccination.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Hyperprogression of Merkel cell carcinoma after avelumab treatment.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Conquering lung cancer: current status and prospects for the future.

Pulmonology·2020
Same author

[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example].

Pneumologie (Stuttgart, Germany)·2018
Same author

PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

[Molecular genetic tests in advanced non-small cell lung cancer: practical relevance].

Deutsche medizinische Wochenschrift (1946)·2014

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Antibody-toxin conjugates, or immunotoxins, are under investigation as novel anticancer therapies.
  • These agents utilize monoclonal antibodies to target tumor-specific antigens, delivering cytotoxic payloads to cancer cells.

Purpose of the Study:

  • To evaluate the potential of immunotoxins as anticancer agents.
  • To identify factors influencing immunotoxin activity in vitro and challenges associated with in vivo administration.

Main Methods:

  • Development of immunotoxins targeting antigens on solid tumors like breast and ovarian carcinoma.
  • In vitro assessment of factors affecting immunotoxin activity, including antigen expression, internalization, toxin type, and antibody class.
  • Evaluation of in vivo challenges such as serum half-life, tumor penetration, tumor heterogeneity, immunogenicity, and cross-reactivity.

Main Results:

  • In vitro immunotoxin activity is influenced by multiple factors, including target antigen density and internalization efficiency.
  • In vivo administration faces hurdles like rapid hepatic uptake, short serum half-life, and poor tumor penetration, potentially limiting efficacy.
  • Tumor heterogeneity, immunogenicity, and off-target effects on normal tissues are significant concerns for clinical application.

Conclusions:

  • Immunotoxins represent a promising strategy for cancer treatment, requiring precise delivery of toxins to cancer cell cytoplasm.
  • Overcoming challenges related to in vivo administration and potential adverse effects is crucial for successful clinical translation.
  • Further development of existing and novel methods is necessary to fully realize the therapeutic potential of immunotoxins in oncology.

Related Experiment Videos